Pancreatic cancer drug development may be entering a new phase. As emerging targeted therapies raise the possibility of a fundamentally different standard of care, sponsors could increasingly confront a familiar but more urgent challenge in oncology: how to generate robust, credible comparative evidence when traditional randomization is no longer feasible, ethical, or aligned with evolving patient and clinical expectations. 

This webinar will examine the growing role of external controls in pancreatic cancer trial design. Our experts will discuss how sponsors can use high-quality patient-level data from historical clinical trials to support hybrid and single-arm studies, contextualize treatment effects, and prepare for regulatory conversations in a fast-moving treatment landscape. 

Join us for this session to explore: 

1. How external controls are being applied in pancreatic cancer trial design  
2. Where hybrid and single-arm studies can provide meaningful comparative context  
3. What defines “fit-for-purpose” patient-level data for regulatory use  
4. How evidence expectations are evolving alongside changes in the standard of care  

We’ll also share exclusive perspectives from Medidata’s recent participation in the pancreatic cancer external control arm validation work with Friends of Cancer Research, presented publicly in April 2026. You’ll learn what makes pancreatic cancer a timely use case for external controls, what evidence standards matter most, and how sponsors can begin planning now for trials designed around the realities of tomorrow’s standard of care.